Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 3/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.35 |
| ▸ | GPR142 | Q7Z601 | 1/20 | 0.35 |
| ▸ | HCRTR1 | O43613 | 12/20 | 0.34 |
| ▸ | HCRTR2 | O43614 | 12/20 | 0.34 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.34 |
| ▸ | PARP1 | P09874 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9612702 | 0.94 | PIK3CA (0.45) | PIK3CAHSD11B1HCRTR1HCRTR2PIK3CG | |
| SCHEMBL9612495 | 0.94 | PIK3CA (0.45) | PIK3CAHSD11B1HCRTR1HCRTR2PIK3CG | |
| SCHEMBL9612760 | 0.93 | PIK3CA (0.47) | PIK3CAHSD11B1HCRTR1HCRTR2PIK3CG | |
| SCHEMBL2725382 | 0.92 | PIK3CA (0.54) | PIK3CAHSD11B1GPR142 | |
| SCHEMBL9612746 | 0.92 | PIK3CA (0.46) | PIK3CAHSD11B1HCRTR1HCRTR2PIK3CG | |
| SCHEMBL9612473 | 0.91 | PIK3CA (0.43) | PIK3CAHSD11B1HCRTR1HCRTR2PIK3CG | |
| SCHEMBL9612738 | 0.91 | PIK3CA (0.43) | PIK3CAHSD11B1HCRTR1HCRTR2 | |
| SCHEMBL9612466 | 0.91 | PIK3CA (0.46) | PIK3CAHSD11B1HCRTR1HCRTR2PIK3CG | |
| SCHEMBL9612490 | 0.90 | PIK3CA (0.46) | PIK3CAHSD11B1HCRTR1HCRTR2PIK3CG | |
| SCHEMBL9612758 | 0.90 | PIK3CA (0.44) | PIK3CAHSD11B1HCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140378436-A9 | Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their use and Manufacture | EXELIXIS, INC. (US) | 2014-12-25 | — | — | US | disclosed |
| US-20140378436-A9 | Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their use and Manufacture | EXELIXIS, INC. (US) | 2014-12-25 | — | — | US | disclosed |
| US-20140024637-A1 | Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their use and Manufacture | EXELIXIS, INC. (US) | 2014-01-23 | — | — | US | disclosed |
| US-20140024637-A1 | Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their use and Manufacture | EXELIXIS, INC. (US) | 2014-01-23 | — | — | US | disclosed |
| WO-2012071509-A2 | BENZOXAZEPINES AS INHIBITORS OF P13K/MTOR AND METHODS OF THEIR USE AND MANUFACTURE | EXELIXIS, INC. (US) | 2012-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140378436-A9 | Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their use and Manufacture | MTOR, RICTOR, PIK3CA | PIK3CA 3/4885HSD11B1 575/4885GPR142 1660/4885 |
| US-20140024637-A1 | Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their use and Manufacture | MTOR, RICTOR, PIK3CA | PIK3CA 3/4885HSD11B1 575/4885GPR142 1660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.